[Effect of HepG2 cells modified with CD80-IgG1 Fc fusion protein on anti-tumor immune response by lymphocytes].
OBJECTIVE
To investigate the anti-tumor immune response of lymphocytes elicited by HepG2 cells modified with CD80-IgG1 Fc fragment fusion protein (CD80-Fc).


METHODS
HepG2 cells were modified with CD80-Fc, then the expression of CD80 on the cell surface was analyzed by flow cytometry (FCM). After mixed lymphocyte-tumour cell reaction (MLTR) of the modified HepG2 cells and peripheral lymphocytes of healthy volunteers, the proliferation and cytotoxicity of the lymphocytes were tested by MTT colorimetry and LDH release assay,respectively.


RESULTS
CD80-Fc could be efficiently bound on HepG2 cells. HepG2 cells modified with CD80-Fc fusion protein dramatically elicited proliferation and cytotoxicity of normal lymphocytes.


CONCLUSIONS
CD80 may play an important role in anti-tumour immune response. HepG2 cells modified with CD80-Fc fusion protein can elicited potent anti-tumor immune response. This fusion protein provides a convenient means for further potential use in immunotherapy of tumor.
Li
Pin
P
Institute of Clinical Immunology, Union Hospital, Fujian Medical University, Fuzhou 350001, China.
Li
He-Jun
HJ
Zhang
Jia-Yong
JY
Shi
Guo-Xun
GX
Zheng
Xiang-Xiong
XX
D000818:Animals; D018122:B7-1 Antigen / Q000235:genetics / Q000276:immunology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D015972:Gene Expression Regulation, Neoplastic / Q000276:immunology; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000235:genetics / Q000276:immunology*; D007074:Immunoglobulin G / Q000235:genetics / Q000276:immunology*; D008214:Lymphocytes / Q000276:immunology* / Q000473:pathology; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology; D011993:Recombinant Fusion Proteins / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D018122:B7-1 Antigen; D007141:Immunoglobulin Fc Fragments; D007074:Immunoglobulin G; D011993:Recombinant Fusion Proteins